bluebird bio 将来の成長

Future 基準チェック /26

bluebird bioは、41.2%と27%でそれぞれ年率41.2%で利益と収益が成長すると予測される一方、EPSはgrowで51.3%年率。

主要情報

41.2%

収益成長率

51.3%

EPS成長率

Biotechs 収益成長	24.9%
収益成長率	27.0%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	16 Apr 2025

今後の成長に関する最新情報

Recent updates

Patient Starts And Capacity Expansion Will Achieve Breakeven

Apr 08 Sustained patient demand and operational efficiency improvements are poised to enhance revenue growth and financial stability by driving cash flow breakeven.

Investors Don't See Light At End Of bluebird bio, Inc.'s (NASDAQ:BLUE) Tunnel And Push Stock Down 38%

Jan 04

bluebird bio, Inc.'s (NASDAQ:BLUE) Revenues Are Not Doing Enough For Some Investors

Nov 15

Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation

Jul 13

Bluebird, Real Endpoints team up to increase access to pricey gene therapy Zynteglo

Oct 04

Bluebird bio names interim finance chief

Sep 26

Bluebird bio jumps 17% on FDA approval of new gene therapy

Sep 19

bluebird bio' chief strategy and financial officer to depart

Sep 12

業績と収益の成長予測

NasdaqGS:BLUE - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2027	351	-126	N/A	N/A	2
12/31/2026	249	-217	N/A	N/A	2
12/31/2025	337	-131	N/A	N/A	1
12/31/2024	84	-241	-263	-260	N/A
9/30/2024	53	-293	-271	-264	N/A
6/30/2024	55	-319	-254	-245	N/A
3/31/2024	46	-301	-248	-238	N/A
12/31/2023	29	-212	-244	-235	N/A
9/30/2023	22	-63	-209	-200	N/A
6/30/2023	9	-52	-236	-227	N/A
3/31/2023	4	-89	-276	-262	N/A
12/31/2022	4	-230	-329	-316	N/A
9/30/2022	5	-431	-447	-436	N/A
6/30/2022	6	-507	-525	-506	N/A
3/31/2022	5	-563	-574	-558	N/A
12/31/2021	4	-563	-659	-636	N/A
9/30/2021	-238	-573	-680	-651	N/A
6/30/2021	-220	-614	-678	-653	N/A
3/31/2021	-21	-480	-493	-468	N/A
12/31/2020	N/A	-561	-499	-470	N/A
9/30/2020	250	-642	-509	-474	N/A
6/30/2020	240	-653	-493	-439	N/A
3/31/2020	54	-828	-684	-616	N/A
12/31/2019	N/A	-555	-641	-564	N/A
9/30/2019	54	-715	-611	-535	N/A
6/30/2019	57	-655	-569	-496	N/A
3/31/2019	51	-605	-526	-459	N/A
12/31/2018	55	-556	-469	-413	N/A
9/30/2018	40	-524	N/A	-379	N/A
6/30/2018	36	-457	N/A	-361	N/A
3/31/2018	45	-382	N/A	-314	N/A
12/31/2017	35	-336	N/A	-281	N/A
9/30/2017	33	-290	N/A	-254	N/A
6/30/2017	27	-288	N/A	-237	N/A
3/31/2017	11	-276	N/A	-228	N/A
12/31/2016	6	-264	N/A	-190	N/A
9/30/2016	6	-239	N/A	-154	N/A
6/30/2016	6	-205	N/A	-143	N/A
3/31/2016	9	-198	N/A	-111	N/A
12/31/2015	14	-167	N/A	-98	N/A
9/30/2015	19	-139	N/A	-81	N/A
6/30/2015	24	-113	N/A	-73	N/A
3/31/2015	25	-63	N/A	-72	N/A
12/31/2014	25	-49	N/A	-60	N/A
9/30/2014	25	-37	N/A	-49	N/A
6/30/2014	25	-26	N/A	-38	N/A

アナリストによる今後の成長予測

収入対貯蓄率: BLUE今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: BLUE今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: BLUE今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: BLUEの収益 ( 27% ) US市場 ( 8.2% ) よりも速いペースで成長すると予測されています。

高い収益成長: BLUEの収益 ( 27% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: BLUEの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/04/28 16:15
終値	2025/04/25 00:00
収益	2024/12/31
年間収益	2024/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

bluebird bio, Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。33

アナリスト	機関
Jack Allen	Baird
Huidong Wang	Barclays
Zhiqiang Shu	Berenberg

bluebird bio 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus EPS estimates upgraded to US$5.66 loss

Consensus EPS estimates fall by 11%, revenue upgraded

Price target decreased by 11% to US$23.25

Consensus EPS estimates upgraded to US$26.75 loss

Price target decreased by 31% to US$26.00

Consensus EPS estimates fall by 11%

Recent updates

New major risk - Share price stability

Patient Starts And Capacity Expansion Will Achieve Breakeven

Consensus EPS estimates upgraded to US$5.66 loss

Gamida Cell Ltd. proposed to acquire bluebird bio, Inc. (NasdaqGS:BLUE) from BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc. and others for approximately $110 million.

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 11%, revenue upgraded

Price target decreased by 11% to US$23.25

SK Capital Partners, LP and The Carlyle Group Inc. (NasdaqGS:CG) entered into an agreement to acquire bluebird bio, Inc. (NasdaqGS:BLUE) for $98.2 million.

Consensus EPS estimates upgraded to US$26.75 loss

Price target decreased by 31% to US$26.00

Investors Don't See Light At End Of bluebird bio, Inc.'s (NASDAQ:BLUE) Tunnel And Push Stock Down 38%

Consensus EPS estimates fall by 11%

New minor risk - Insider selling

Bluebird Bio, Inc. Announces Updated Data from Patients with Beta-Thalassemia Who Require Regular Blood Transfusions Treated with Betibeglogene Autotemcel (Beti-Cel, Approved Commercially as ZYNTEGL) in Clinical Studies

New major risk - Share price stability

Insufficient new directors

Price target decreased by 24% to US$2.19

bluebird bio, Inc.'s (NASDAQ:BLUE) Revenues Are Not Doing Enough For Some Investors

New major risk - Revenue and earnings growth

Forecast to breakeven in 2026

bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1)

bluebird bio: Scientific Success And Financial Success, And The Gap Between

bluebird bio, Inc., Annual General Meeting, Nov 06, 2024

bluebird bio Announces Receipt of Expected Notices from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5250(c)(1)

bluebird bio, Inc. Provides Revenue Guidance for the Third and Fourth Quarter of 2024

Price target decreased by 13% to US$3.67

Price target decreased by 11% to US$3.78

bluebird bio's Flight Through Financial Fog And Fierce Rivals

bluebird bio, Inc. Announces Chief Financial Officer Changes, Effective June 10, 2024

bluebird bio, Inc. announced delayed 10-Q filing

Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Bluebird Bio Inc

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio Is Priced Below IP Value

Price target increased by 8.0% to US$5.00

Bluebird Bio: Innovative Therapies, Monetary Setbacks

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

New major risk - Shareholder dilution

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

bluebird bio, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Consensus revenue estimates fall by 13%

Price target decreased by 8.2% to US$6.61

Bluebird Bio Inc. Presents Long-Term Data At Ash Support Beti-Ccel as A Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusion Independence and Normal or Near- Normal- Normal- Normal-Normal Adult Hb Levels

Bluebird Bio Details Plans for the Commercial Launch of Lyfgenia(Tm) Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and A History of Vaso-Occlusive Events

Now 31% undervalued after recent price drop

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

Bluebird Bio, Inc. to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology Annual Meeting and Exposition

Now 24% undervalued after recent price drop

bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Is bluebird bio (NASDAQ:BLUE) In A Good Position To Invest In Growth?

New minor risk - Insider selling

President recently sold US$60k worth of stock

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation

bluebird bio, Inc. Announces FDA Priority Review of the Biologics License Application for Lovotibeglogene Autotemcel (Lovo-Cel) for Patients with Sickle Cell Disease (Scd) 12 Years and Older with a History of Vaso-Occlusive Events

Consensus revenue estimates decrease by 26%, EPS upgraded

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

bluebird bio, Inc. Appoints Joseph Vittiglio, JD as Chief Business and Legal Officer

U.S. Food and Drug Administration Lifts Partial Clinical Hold for bluebird bio, Inc.’s Sickle Cell Disease Studies for Patients Under the Age of 18

Bluebird Bio, Inc. Presents New and Updated Data At the 64Th American Society of Hematology Annual Meeting and Exposition

An unknown buyer entered into a definitive agreement to acquire SKYSONA & ZYNTEGLO of bluebird bio, Inc. (NasdaqGS:BLUE) for approximately $100 million.

Consensus forecasts updated

Less than half of directors are independent

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

bluebird bio, Inc. Appoints Christopher Krawtschuk as Treasurer, Principal Financial Officer and Principal Accounting Officer